AHF: Gilead's Greed Kills Promise of Lenacapavir for HIV Prevention
The U.S. Food and Drug Administration approved use of Gilead's HIV treatment medication, lenacapavir, for use to prevent HIV infection earlier today, an action which was followed by news that Gilead intends to price the HIV prevention medication at over $28,000 per patient, per year. AIDS Healthcare Foundation (AHF) President Michael Weinstein sharply criticized Gilead's outrageous pricing in the following statement:
'What could be an extraordinary game changer for HIV prevention is being completely undermined by Gilead's greed. Charging $28,218 a year will drastically limit the availability of the drug. Gilead continues to feast on tens of billions of dollars, much of which is public funding for their HIV portfolio, at the expense of people living with or at risk of acquiring HIV. Gilead is sacrificing control of HIV on the altar of their bottom line.'
AIDS Healthcare Foundation (AHF), the world's largest HIV/AIDS healthcare organization, provides cutting-edge medicine and advocacy to more than 2.3 million individuals across 48 countries, including the U.S. and in Africa, Latin America/Caribbean, the Asia/Pacific Region, and Eastern Europe. In January 2025, AHF received the MLK, Jr. Social Justice Award, The King Center's highest recognition for an organization leading work in the social justice arena. To learn more about AHF, visit us online at AIDShealth.org, find us on Facebook, and follow us on Instagram, Twitter, and TikTok.
View source version on businesswire.com:https://www.businesswire.com/news/home/20250618031796/en/
CONTACT: Ged Kenslea, AHF Sr. Comms Dir.
(323) 791-5526
[email protected]
KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA
INDUSTRY KEYWORD: FDA STATE/LOCAL PUBLIC POLICY HEALTHCARE REFORM PHARMACEUTICAL PHILANTHROPY ADVOCACY GROUP OPINION INFECTIOUS DISEASES PUBLIC POLICY/GOVERNMENT LGBTQ+ FOUNDATION BIOTECHNOLOGY AIDS CONSUMER HEALTH
SOURCE: AIDS Healthcare Foundation
Copyright Business Wire 2025.
PUB: 06/18/2025 05:38 PM/DISC: 06/18/2025 05:36 PM
http://www.businesswire.com/news/home/20250618031796/en
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Wall Street Journal
26 minutes ago
- Wall Street Journal
Scientists Are Finally Making Progress Against Alzheimer's
Buck up, baby boomers. Sixty may not be the new 40, but 80 could soon be the new 60. A trove of new Alzheimer's research suggests that medicines and lifestyle changes can not only slow but prevent, even reverse, the debilitating disease. Alzheimer's is characterized by a buildup of amyloid plaque and tangles of tau proteins in the brain. They trigger inflammation, which in turn causes cognitive decline and neuron death. Scientists don't know exactly what causes this destructive cascade. The disease's complexity stymied the quest for treatments for decades, but no more. Scientists are learning quickly.
Yahoo
an hour ago
- Yahoo
Wells Fargo Sticks with Overweight on UnitedHealth (UNH), Trims Target to $267
UnitedHealth Group Inc. (NYSE:UNH) is one of the best defensive stocks to invest in according to analysts. At the time of writing this article, UnitedHealth ranks among the 10 biggest year-to-date decliners, which have lost over 50% among U.S.-listed stocks with a market capitalization exceeding $2 billion. The company, which was marred by government investigations, operational failures, and leadership changes, reported mixed Q2 2025 earnings results at the end of July. Those results have been unable to shore up the share price, as the long-term growth outlook is still murky. A close-up of a healthcare professional studying a computer screen with data while consulting with a patient. The company guided for 2025 adjusted EPS to be over $16, which was significantly below Bloomberg's consensus expectations of $20.4. Seeing the brighter side, Jeff Jonas, portfolio manager at Gabelli Funds, called the guidance highly conservative and believes that it will be easier for the company to beat such low expectations. However, the steep correction and valuation discount have attracted analysts' interest, with around two-thirds of them having a Buy or equivalent rating. One of the analysts who maintains an optimistic view is Wells Fargo's Stephen Baxter. On August 4, Baxter maintained an Overweight rating on UnitedHealth but lowered his price target to $267 from $306. The revision followed a recently held management meeting where he assessed the company's updated outlook. According to the analyst, UnitedHealth's management remains confident in the company's ability to meet its reset 2025 guidance. In his view, management is taking a cautious but disciplined approach in factoring in cost trends and margin recovery. Baxter views this conservatism positively, suggesting it reduces the risk of further downside revisions. UnitedHealth Group Inc. (NYSE:UNH) is a healthcare company that provides health insurance and healthcare solutions in the U.S. and globally under the UnitedHealthcare and Optum brands. While we acknowledge the potential of UNH as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Most Oversold S&P 500 Stocks So Far in 2025 and 10 Most Oversold Semiconductor Stocks So Far in 2025. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Actor with colorectal cancer shares simple sign that he ignored: ‘I had no idea'
James van der Beek has revealed the first warning sign of his colon cancer — and it's one that did not seem alarming at the time. The "Dawson's Creek" actor, 48, who announced his colorectal cancer diagnosis in November 2024, recently told Healthline that "there wasn't any red flag or something glaring." "I was healthy. I was doing the cold plunge," he said. "I was in amazing cardiovascular shape, and I had stage 3 cancer, and I had no idea." Colorectal Cancer Diagnoses Soar Among Younger Adults For One Key Reason The one symptom that he did experience was a change in bowel movements, which the actor chalked up to an effect of his coffee consumption. "Before my diagnosis, I didn't know much about colorectal cancer," van der Beek said. "I didn't even realize the screening age [had] dropped to 45; I thought it was still 50." Read On The Fox News App He ultimately underwent a colonoscopy, which revealed that the actor had stage 3 colon cancer. Professor Eitan Friedman, M.D., Ph.D., an oncologist and founder of The Suzanne Levy-Gertner Oncogenetics Unit at the Sheba Medical Center in Israel, confirmed that changes in bowel habits is the primary red flag that should raise the suspicion of colorectal cancer. Others include fatigue as a result of anemia, blood in stool, weight loss, loss of appetite and abdominal discomfort, Friedman, who has not treated van der Beek, told Fox News Digital. Dr. Erica Barnell, M.D., Ph.D., a physician-scientist at Washington University School of Medicine — and co-founder and chief medical officer at Geneoscopy — noted that van der Beek's experience of having no "glaring" signs is common. "Many colorectal cancers develop silently, without obvious symptoms," Barnell, who also did not treat the actor, told Fox News Digital. "By the time symptoms appear, the disease may already be advanced." Symptoms are "especially worrisome" for those 45 and older who have at least one first-degree relative with colon cancer or other GI malignancies, and those with active inflammatory bowel disease, such as ulcerative colitis or Crohn's disease, added Friedman, who is also an advisory board member at SpotitEarly, a startup that offers an at-home breath test to detect early-stage cancer signals. The overall chance of an average-risk person getting colorectal cancer over a lifetime is 4% to 5%, according to Friedman. "Colonoscopy at age 45 onwards, at five- to 10-year intervals, has been shown to lead to early detection of polyps that have the potential to become malignant, and to allow for their removal as an effective means of minimizing the risk of malignant transformation," he said. Click Here To Sign Up For Our Health Newsletter Unfortunately, Barnell noted, "screening compliance in the U.S. remains below national targets, and gaps are widest in rural, low-income and minority communities." To help close those gaps, she called for greater access to "accurate, noninvasive screening technologies," along with efforts to increase public awareness. "Most people don't like talking about bowel habits, but paying attention to changes can save your life," Barnell said. "Screening gives us the chance to find problems early — often before you feel sick — and that can make all the difference." For more Health articles, visit Fox News Digital reached out to van der Beek's representative for article source: Actor with colorectal cancer shares simple sign that he ignored: 'I had no idea' Solve the daily Crossword
